Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.51 |
| ▸ | HTR3A | P46098 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | RHEB | Q15382 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11576431 | 0.90 | HPGD (0.46) | HTR1AHTR3AHPGDPKMSMN1; SMN2 | |
| SCHEMBL11756716 | 0.87 | HTR1A (0.45) | HTR1AHTR3AHPGDPKMSMN1; SMN2 | |
| SCHEMBL11763884 | 0.85 | SLC6A4 (0.44) | HTR1AHTR3AHPGDPKMSMN1; SMN2 | |
| SCHEMBL11761224 | 0.85 | HTR1A (0.51) | HTR1AHTR3AHPGDPKMSMN1; SMN2 | |
| SCHEMBL11610674 | 0.84 | HTR1A (0.51) | HTR1AHTR3AHPGDPKMSMN1; SMN2 | |
| SCHEMBL11706102 | 0.83 | HTR1A (0.48) | HTR1AHTR3AHPGDPKMSMN1; SMN2 | |
| SCHEMBL11759797 | 0.82 | MEN1 (0.44) | HTR1AHTR3AHPGDAGBL2MAPT | |
| SCHEMBL11838305 | 0.81 | AGBL2 (0.47) | HTR1AHTR3AHPGDAGBL2MAPT | |
| SCHEMBL11615331 | 0.80 | HTR1A (0.48) | HTR1AHTR3AHPGDPKMSMN1; SMN2 | |
| SCHEMBL11613170 | 0.79 | AGBL2 (0.66) | HTR1AHTR3AHPGDPKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| EP-1981497-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| US-4089861-A | NEUROLEPTIC AGENT | HOFFMANN-LA ROCHE, INC. (US) | 1978-05-16 | — | — | US | disclosed |
| US-4044010-A | NEUROLEPTIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1977-08-23 | — | — | US | disclosed |
| US-4035346-A | ANTISTATIC | E. I. DU PONT DE NEMOURS AND CO. (US) | 1977-07-12 | — | — | US | disclosed |
| US-4011222-A | NEUROLEPTIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1977-03-08 | — | — | US | disclosed |
| US-4006123-A | Conductive aliphatic polyester or polyetherester having units containing phosphonium sulfonate groups | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-02-01 | — | — | US | disclosed |
| US-3996229-A | DEPRESSANTS, NEUROLEPTICS | HOFFMANN-LA ROCHE INC. (US) | 1976-12-07 | — | — | US | disclosed |
| US-3966737-A | NEUROLEPTIC | HOFFMANN-LA ROCHE INC. (US) | 1976-06-29 | — | — | US | disclosed |
| US-3954764-A | NEUROLEPTIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | GPR119, PER2, MTNR1B | HTR1A 15/4885HTR3A 98/4885HPGD 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.